logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
06/08/2025
US stocks: high-performance stocks rose in the morning, Astera Labs surged more than 25%, Shopify and Novavax Pharmaceuticals rose more than 21%, Centrus Energy rose more than 18%.
Latest
6 m ago
Walmart's stock rises more than 3%, July marks a record high for Walmart+ membership.
6 m ago
On Wednesday, Walmart rose over 3% to $102.68. On the news front, Morgan Stanley recently released a research report maintaining a "buy" rating on Walmart with a target price of $115. The bank stated that Walmart's paid membership service Walmart+ reached a record high in July 2025, which signifies the continued effectiveness of the retail giant's strategic layout in the e-commerce field. According to Morgan Stanley's AlphaWise monthly consumer pulse survey data for July, Walmart+ had approximately 28.3 million members (adjusted for user response error to 18.4 million), equivalent to a household penetration rate of about 22% in the United States (adjusted to 14%). This figure represents an increase of 1.1 million from June, the highest record since the survey began in September 2020. Over a rolling three-month period, Walmart+'s membership grew by approximately 27% year-over-year.
12 m ago
Spot palladium fell 3% to $1,136 per ounce.
13 m ago
Knorr and Nord respond to declining market share: sales of weight loss drugs in China are still on the rise.
13 m ago
In the Chinese market, sales of Novo Nordisk's semaglutide, a diabetes drug, also fell by around 11% in the first half of this year. During the investor conference call after the financial report was released, Maziar Mike Doustdar, the current Vice President of International Business at Novo Nordisk and soon-to-be CEO after taking over from Zhou Fude on August 7th, responded to investors' concerns about the competitive challenges facing semaglutide in the Chinese market. Doustdar stated that while sales of GLP-1 diabetes drugs in China have declined, sales of weight loss drugs are gradually increasing. He explained that the decline in diabetes drug sales was due to changes in distributor inventories; and that the semaglutide weight loss drug, which was only approved last year, is currently in the ramp-up stage and has not yet penetrated further into second, third, and fourth-tier cities. (Yicai)
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.